Clinical trial
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of…
NCT00281294 · PDL BioPharma, Inc., Industry · Terminated
Key facts
| NCT number | NCT00281294 |
|---|---|
| Title | A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis |
| Official title | A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis |
| Lead sponsor | PDL BioPharma, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | Fontolizumab |
| Enrollment | 40 |
| Start date | Dec 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Jan 24, 2006 |
| Last update posted | Aug 5, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: